248 related articles for article (PubMed ID: 29076303)
1. Anti-VEGF Therapy for Diabetic Eye Diseases.
Bahrami B; Hong T; Gilles MC; Chang A
Asia Pac J Ophthalmol (Phila); 2017; 6(6):535-545. PubMed ID: 29076303
[TBL] [Abstract][Full Text] [Related]
2. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Ajlan RS; Silva PS; Sun JK
Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
[TBL] [Abstract][Full Text] [Related]
3. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
[TBL] [Abstract][Full Text] [Related]
4. Diabetic macular edema.
Lang GE
Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept for the treatment of diabetic macular edema.
Harkins KA; Haschke M; Do DV
Immunotherapy; 2016 May; 8(5):503-10. PubMed ID: 26907516
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic targets in diabetic macular edema: Beyond VEGF.
Urias EA; Urias GA; Monickaraj F; McGuire P; Das A
Vision Res; 2017 Oct; 139():221-227. PubMed ID: 28993218
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
Uludag G; Hassan M; Matsumiya W; Pham BH; Chea S; Trong Tuong Than N; Doan HL; Akhavanrezayat A; Halim MS; Do DV; Nguyen QD
Expert Opin Biol Ther; 2022 Oct; 22(10):1275-1291. PubMed ID: 35818801
[TBL] [Abstract][Full Text] [Related]
8. What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?
Agarwal A; Sarwar S; Sepah YJ; Nguyen QD
Curr Opin Ophthalmol; 2015 May; 26(3):177-83. PubMed ID: 25784111
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
10. Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.
Couturier A; Rey PA; Erginay A; Lavia C; Bonnin S; Dupas B; Gaudric A; Tadayoni R
Ophthalmology; 2019 Dec; 126(12):1685-1694. PubMed ID: 31383483
[TBL] [Abstract][Full Text] [Related]
11. The Short-term Effect of a Single Lapse in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice.
Yalamanchili SP; Maatouk CM; Enwere DU; Conti TF; Hom GL; Briskin IN; Greenlee TE; Babiuch AS; Singh RP
Am J Ophthalmol; 2020 Nov; 219():215-221. PubMed ID: 32640254
[TBL] [Abstract][Full Text] [Related]
12. Current concepts of pharmacotherapy of diabetic macular edema.
Haritoglou C; Maier M; Neubauer AS; Augustin AJ
Expert Opin Pharmacother; 2020 Mar; 21(4):467-475. PubMed ID: 31957495
[No Abstract] [Full Text] [Related]
13. The role of aflibercept in the management of diabetic macular edema.
Chang AA; Hong T; Ewe SY; Bahrami B; Broadhead GK
Drug Des Devel Ther; 2015; 9():4389-96. PubMed ID: 26273198
[TBL] [Abstract][Full Text] [Related]
14. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications.
Zhang J; Zhang J; Zhang C; Zhang J; Gu L; Luo D; Qiu Q
Cells; 2022 Oct; 11(21):. PubMed ID: 36359761
[TBL] [Abstract][Full Text] [Related]
15. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM; Ciulla TA
Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.
Dervenis N; Mikropoulou AM; Tranos P; Dervenis P
Adv Ther; 2017 Jun; 34(6):1270-1282. PubMed ID: 28484955
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
Ehlers JP; Yeh S; Maguire MG; Smith JR; Mruthyunjaya P; Jain N; Kim LA; Weng CY; Flaxel CJ; Schoenberger SD; Kim SJ
Ophthalmology; 2022 Jan; 129(1):88-99. PubMed ID: 34446301
[TBL] [Abstract][Full Text] [Related]
19. Adherence to Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs in Diabetic Macular Edema in an Egyptian Population: A Health Belief Model.
Habib AE; Abdel-Kader AA; Eissa IM; Awadein A
Curr Eye Res; 2019 Mar; 44(3):303-310. PubMed ID: 30383436
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF therapy for diabetic macular edema.
Stewart MW
Curr Diab Rep; 2014 Aug; 14(8):510. PubMed ID: 24919750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
